CERNER (CERN) 10-Q 29 Apr 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Apr. 23, 2020
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Entity File Number	0-15386
Entity Registrant Name	CERNER CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2800 Rockcreek Parkway
Entity Address, City or Town	North Kansas City,
Entity Address, State or Province	MO
Entity Tax Identification Number	43-1196944
Entity Address, Postal Zip Code	64117
City Area Code	816
Local Phone Number	221-1024
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	CERN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		304,348,600
Entity Central Index Key	0000804753
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 28, 2019
Current assets:
Cash and cash equivalents	$ 285,412	$ 441,843
Short-term investments	113,363	99,931
Receivables, net	1,151,028	1,139,595
Inventory	23,457	23,182
Prepaid Expense and Other Assets, Current	390,346	392,073
Total current assets	1,963,606	2,096,624
Property and equipment, net	1,835,138	1,858,772
Right-of-use assets	128,095	123,155
Software development costs, net	954,201	939,859
Goodwill	881,092	883,158
Intangible assets, net	350,187	364,439
Long-term investments	411,793	419,419
Other assets	212,318	209,196
Total assets	6,736,430	6,894,622
Current liabilities:
Accounts payable	295,950	273,440
Deferred revenue	316,611	360,025
Accrued payroll and tax withholdings	248,853	245,843
Other current liabilities	157,072	148,140
Total current liabilities	1,018,486	1,027,448
Long-term Debt	1,338,417	1,038,382
Deferred income taxes	378,530	377,657
Other liabilities	137,918	133,807
Total liabilities	2,873,351	2,577,294
Shareholders' Equity:
Common stock, $0.01 par value, 500,000,000 shares authorized, 370,178,300 shares issued at March 31, 2020 and 367,634,796 shares issued at December 28, 2019	3,702	3,676
Additional paid-in capital	2,054,252	1,905,171
Retained earnings	6,022,256	5,934,909
Treasury stock, 65,919,144 shares at March 31, 2020 and 56,723,546 shares at December 28, 2019	(4,057,768)	(3,407,768)
Accumulated other comprehensive loss, net	(159,363)	(118,660)
Total shareholders' equity	3,863,079	4,317,328
Total liabilities and shareholders' equity	$ 6,736,430	$ 6,894,622
Common stock, par value	$ 0.01
Common Stock, Shares Authorized	500,000,000
Common stock, shares issued	370,178,300	367,634,796
Treasury Stock, Shares	65,919,144	56,723,546

Consolidated Statements Of Oper

Consolidated Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 30, 2019
Revenues	$ 1,411,741	$ 1,389,877
Costs and expenses:
Cost of Goods and Services Sold	254,416	253,204
Sales and client service	636,649	640,187
Software development (Includes amortization of $61,011 and $56,245, respectively)	185,320	180,361
General and administrative	139,852	96,196
Amortization of acquisition-related intangibles	17,128	21,985
Total costs and expenses	1,233,365	1,191,933
Operating earnings	178,376	197,944
Other income, net	5,595	8,432
Earnings before income taxes	183,971	206,376
Income taxes	(36,812)	(40,157)
Net earnings	$ 147,159	$ 166,219
Basic earnings per share	$ 0.48	$ 0.51
Diluted earnings per share	$ 0.47	$ 0.51
Basic weighted average shares outstanding	309,657	324,573
Diluted weighted average shares outstanding	312,240	327,003
Software development, amortization	$ 61,011	$ 56,245

Consolidated Statements Of Comp

Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 30, 2019
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Net earnings	$ 147,159	$ 166,219
Foreign currency translation adjustment and other (net of taxes (benefit) of $425 and $(183), respectively)	(20,546)	2,321
Unrealized loss on cash flow hedge (net of tax benefit of $6,350 for the three months ended March 31, 2020	(19,308)	0
Unrealized holding gain (loss) on available-for-sale investments (net of taxes (benefit) of $(279) and $210, respectively)	(849)	637
Comprehensive income	106,456	169,177
Foreign currency translation adjustment and other, taxes (benefit)	425	(183)
Unrealized loss on cash flow hedge, taxes (benefit)	(6,350)
Change in net unrealized holding gain (loss) on available-for-sale investments, taxes (benefit)	$ (279)	$ 210

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings	$ 147,159	$ 166,219
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	172,646	166,671
Share-based compensation expense	35,031	19,860
Provision for deferred income taxes	10,449	3,998
Investment gains	477	0
Changes in assets and liabilities:
Receivables, net	(22,774)	13,789
Inventory	(296)	928
Prepaid expenses and other	(13,681)	(13,318)
Accounts payable	8,539	(10,891)
Accrued income taxes	1,105	4,256
Deferred revenue	(42,310)	(61,547)
Other accrued liabilities	(11,885)	27,301
Net cash provided by operating activities	283,506	317,266
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital purchases	(49,248)	(119,261)
Capitalized software development costs	(73,855)	(74,551)
Purchases of investments	(39,194)	(90,953)
Sales and maturities of investments	36,112	110,104
Purchase of other intangibles	(9,682)	(8,994)
Payments to Acquire Businesses, Net of Cash Acquired	744	0
Net cash used in investing activities	(136,611)	(183,655)
CASH FLOWS FROM FINANCING ACTIVITIES:
Long-term debt issuance	300,000	0
Proceeds from exercise of stock options	118,203	15,281
Payments to taxing authorities in connection with shares directly withheld from associates	(4,517)	(1,730)
Treasury stock purchases	(650,000)	(20,542)
Dividends paid	56,047	0
Other financing activities	(3,600)	0
Net cash used in financing activities	(295,961)	(6,991)
Effect of exchange rate changes on cash and cash equivalents	(7,365)	2,415
Net increase (decrease) in cash and cash equivalents	(156,431)	129,035
Cash and cash equivalents at beginning of period	441,843	374,126
Cash and cash equivalents at end of period	$ 285,412	$ 503,161

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity Statement - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Retained Earnings [Member]Cumulative Effect, Period of Adoption, Adjustment	Treasury Stock [Member]	AOCI Attributable to Parent [Member]
Balance at Dec. 29, 2018		$ 3,622	$ 1,559,562	$ 5,576,525		$ (2,107,768)	$ (103,552)
Common stock, shares issued at Dec. 29, 2018		362,213,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options		$ 7	11,716
Exercise of stock options, shares		706,000
Employee share-based compensation expense			19,860
Other comprehensive income (loss)							2,958
Net earnings	$ 166,219			166,219
Balance at Mar. 30, 2019		$ 3,629	1,591,138	5,742,744		(2,107,768)	(100,594)
Common stock, shares issued at Mar. 30, 2019		362,919,000
Balance at Dec. 28, 2019	$ 4,317,328	$ 3,676	1,905,171	5,934,909	$ (4,606)	(3,407,768)	(118,660)
Common stock, shares issued at Dec. 28, 2019	367,634,796	367,635,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options		$ 26	114,050
Exercise of stock options, shares		2,543,000
Employee share-based compensation expense			35,031
Treasury Stock, Value, Acquired, Cost Method	$ 650,000					(650,000)
Dividends, Cash				55,206
Other comprehensive income (loss)							(40,703)
Net earnings	147,159			147,159
Balance at Mar. 31, 2020	$ 3,863,079	$ 3,702	$ 2,054,252	$ 6,022,256		$ (4,057,768)	$ (159,363)
Common stock, shares issued at Mar. 31, 2020	370,178,300	370,178,000

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Mar. 31, 2020
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Supplemental Disclosures of Cash Flow Information Three Months Ended (In thousands) 2020 2019 Cash paid during the period for: Interest (including amounts capitalized of $4,633 and $3,797, respectively) $ 11,811 $ 7,288 Income taxes, net of refunds 2,869 22,511 Non-cash items: Lease liabilities recorded upon the commencement of operating leases 17,762 15,627

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information details - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 30, 2019
Supplemental Cash Flow Elements [Abstract]
Interest Paid, Capitalized	$ 4,633	$ 3,797
Interest Paid	11,811	7,288
Income Taxes Paid, Net	2,869	22,511
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$ 17,762	$ 15,627

Interim Statement Presentation

Interim Statement Presentation (Notes)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Interim Statement Presentation	Interim Statement Presentation Basis of Presentation The condensed consolidated financial statements included herein have been prepared by Cerner Corporation ("Cerner," the "Company," "we," "us" or "our") without audit, pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our latest annual report on Form 10-K. In management's opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the financial position and the results of operations and cash flows for the periods presented. Our interim results as presented in this Form 10-Q are not necessarily indicative of the operating results for the entire year. The condensed consolidated financial statements were prepared using GAAP. These principles require us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results could differ from those estimates. Fiscal Period End Prior to fiscal year 2020, our first fiscal quarter ended on the Saturday closest to March 31. The first quarter of 2019 consisted of 91 days and ended on March 30, 2019. In December 2019, our Board of Directors approved the change of our fiscal year to a calendar year, commencing with fiscal year 2020. Accordingly, our 2020 first fiscal quarter was extended and ran from December 29, 2019 to March 31, 2020; consisting of 94 days. All references to periods in these notes to condensed consolidated financial statements represent the respective periods described above ending on March 31, 2020 and March 30, 2019, unless otherwise noted. Supplemental Disclosures of Cash Flow Information Three Months Ended (In thousands) 2020 2019 Cash paid during the period for: Interest (including amounts capitalized of $4,633 and $3,797, respectively) $ 11,811 $ 7,288 Income taxes, net of refunds 2,869 22,511 Non-cash items: Lease liabilities recorded upon the commencement of operating leases 17,762 15,627 Accounting Pronouncements Adopted in 2020 Credit Losses on Financial Instruments. In the first quarter of 2020, we adopted new guidance regarding impairment assessment for certain financial assets. Refer to Notes (3) and (4) for further details. Collaborative Arrangements. In November 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 , which clarifies when transactions between participants in a collaborative arrangement are within the scope of the FASB's recent revenue standard (Topic 606). Such guidance clarifies revenue recognition and financial statement presentation for transactions between collaboration participants. We adopted ASU 2018-18 in the first quarter of 2020. Such guidance did not have an impact on our consolidated financial statements and related disclosures. Recently Issued Accounting Pronouncements Reference Rate Reform. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform, such as the upcoming discontinuance of the London Interbank Offered Rate ("LIBOR"). The accommodations within ASU 2020-04 may be applied prospectively from the beginning of our 2020 first quarter through December 31, 2022. We are currently evaluating the effect that ASU 2020-04 may have on our contracts that reference LIBOR, specifically, our Third Amended and Restated Credit Agreement (as amended, the "Credit Agreement") and related interest rate swap. As of the date of this filing, we have not elected to apply any of the provisions of this standard.

Revenue from Contracts with Cus

Revenue from Contracts with Customers (Notes)	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Revenue Recognition Disaggregation of Revenue The following table presents revenues disaggregated by our business models: Three Months Ended 2020 2019 (In thousands) Domestic International Total Domestic International Total Licensed software $ 146,497 $ 11,535 $ 158,032 $ 140,445 $ 14,032 $ 154,477 Technology resale 44,449 7,038 51,487 49,158 6,382 55,540 Subscriptions 86,936 7,449 94,385 77,702 6,589 84,291 Professional services 452,784 58,562 511,346 437,229 53,210 490,439 Managed services 279,736 29,618 309,354 277,325 27,068 304,393 Support and maintenance 223,416 50,265 273,681 226,481 50,482 276,963 Reimbursed travel 12,597 859 13,456 22,490 1,284 23,774 Total revenues $ 1,246,415 $ 165,326 $ 1,411,741 $ 1,230,830 $ 159,047 $ 1,389,877 The following table presents our revenues disaggregated by timing of revenue recognition: Three Months Ended 2020 2019 (In thousands) Domestic International Total Domestic International Total Revenue recognized over time $ 1,165,515 $ 153,444 $ 1,318,959 $ 1,135,982 $ 142,211 $ 1,278,193 Revenue recognized at a point in time 80,900 11,882 92,782 94,848 16,836 111,684 Total revenues $ 1,246,415 $ 165,326 $ 1,411,741 $ 1,230,830 $ 159,047 $ 1,389,877 Transaction Price Allocated to Remaining Performance Obligations As of March 31, 2020, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts approximates $13.47 billion of which we expect to recognize approximately 30% of the revenue over the next 12 months and the remainder thereafter. Contract Liabilities Customer payments received in advance of satisfaction of the related performance obligations are deferred as contract liabilities. Such amounts are classified in our condensed consolidated balance sheets as deferred revenue. During the three months ended March 31, 2020, we recognized $128 million of revenues that were included in our contract liability balance at the beginning of such period. Significant Customers A certain customer within our Domestic segment comprised 17% and 10% of our consolidated revenues for the first three months of 2020 and 2019, respectively.

Receivables

Receivables	3 Months Ended
	Mar. 31, 2020
Receivables [Abstract]
Receivables	Receivables A summary of net receivables is as follows: (In thousands) March 31, 2020 December 28, 2019 Client receivables $ 1,274,158 $ 1,245,670 Less: Allowance for doubtful accounts 123,130 106,075 Total receivables, net $ 1,151,028 $ 1,139,595 A reconciliation of the beginning and ending amount of our allowance for doubtful accounts is as follows: (In thousands) Allowance for doubtful accounts - balance at December 28, 2019 $ 106,075 Cumulative effect of accounting change (ASU 2016-13) 4,606 Additions charged to costs and expenses 15,678 Deductions (3,229) Allowance for doubtful accounts - balance at March 31, 2020 $ 123,130 During the first three months of 2020 and 2019, we received total client cash collections of $1.37 billion and $1.36 billion, respectively. Expected Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which provides a new impairment model for certain financial assets that is based on expected losses rather than incurred losses. Such guidance impacts how we determine our allowance for estimated uncollectible client receivables. The standard requires use of the modified retrospective (cumulative effect) transition approach as of the beginning of the first reporting period in which the guidance was effective, which for the Company was the first quarter of 2020. Under this transition method, the cumulative effect from prior periods upon applying this new guidance was recognized in our condensed consolidated balance sheets as of December 29, 2019. We did not recast comparative periods. A summary of such cumulative effect adjustment is as follows: (In thousands) Increase/(Decrease) Receivables, net $ (4,606) Retained earnings (4,606) The cumulative effect adjustment is the result of providing an allowance on unbilled client receivables, for which we have an unconditional right to invoice and receive payment in the future. Our estimates of expected credit losses for client receivables at both December 29, 2019 and March 31, 2020, were primarily based on historical credit loss experience and adjustments for certain asset-specific risk characteristics (i.e. known client financial hardship or bankruptcy). Exposure to credit losses may increase if our clients are adversely affected by changes in healthcare laws, reimbursement or payor models; economic pressures or uncertainty associated with local

Investments

Investments	3 Months Ended
	Mar. 31, 2020
Investments [Abstract]
Investments	Investments Available-for-sale investments at March 31, 2020 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 149,756 $ — $ — $ 149,756 Time deposits 60,614 — — 60,614 Total cash equivalents 210,370 — — 210,370 Short-term investments: Time deposits 14,737 — — 14,737 Commercial paper 5,000 — (26) 4,974 Government and corporate bonds 79,298 69 (304) 79,063 Total short-term investments 99,035 69 (330) 98,774 Long-term investments: Government and corporate bonds 86,192 50 (853) 85,389 Total available-for-sale investments $ 395,597 $ 119 $ (1,183) $ 394,533 Available-for-sale investments at December 28, 2019 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 185,666 $ — $ — $ 185,666 Time deposits 64,286 — — 64,286 Total cash equivalents 249,952 — — 249,952 Short-term investments: Time deposits 2,506 — — 2,506 Government and corporate bonds 83,272 52 (11) 83,313 Total short-term investments 85,778 52 (11) 85,819 Long-term investments: Government and corporate bonds 96,186 91 (67) 96,210 Total available-for-sale investments $ 431,916 $ 143 $ (78) $ 431,981 We sold available-for-sale investments for proceeds of $5 million during the three months ended March 31, 2020, resulting in insignificant losses in the period. Other Investments At March 31, 2020 and December 28, 2019, we had investments in equity securities that do not have readily determinable fair values of $315 million and $314 million, respectively, accounted for in accordance with Accounting Standards Codification Topic ("ASC") 321, Investments-Equity Securities . Such investments are included in long-term investments in our condensed consolidated balance sheets. We did not record any changes in the measurement of such investments during the three months ended March 31, 2020 and March 30, 2019, respectively. Impairment Assessment We adopted ASU 2016-13 in the first quarter of 2020, which made certain amendments to the model used to assess available-for-sale debt securities for impairment. Such guidance provides that an available-for-sale debt security is impaired if the fair value of the security is less than its amortized cost basis. A determination is made whether the decline in fair value below the amortized cost basis has resulted from a credit loss or other factors, such as market liquidity or changes in interest rates. Impairment related to credit losses is recognized in net earnings, whereas impairment related to other factors is recognized as a component of accumulated other comprehensive loss, net. During the three months ended March 31, 2020, we did not recognize any impairment on our available-for-sale debt securities through net earnings.

Debt

Debt	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Debt Disclosure	Long-term Debt The following is a summary of indebtedness outstanding: (In thousands) March 31, 2020 December 28, 2019 Credit agreement loans due May 5, 2024 $ 600,000 $ 600,000 Senior notes: Series 2020-A due March 11, 2030 300,000 — Series 2015-A due February 15, 2022 225,000 225,000 Series 2015-B due February 14, 2025 200,000 200,000 Other 14,162 14,162 Total indebtedness 1,339,162 1,039,162 Less: debt issuance costs (745) (780) Long-term debt $ 1,338,417 $ 1,038,382 Credit Agreement As of March 31, 2020, the interest rate on revolving credit loans outstanding under our Credit Agreement was 1.60% based on LIBOR plus the applicable spread. We are exposed to market risk from fluctuations in the variable interest rates on outstanding indebtedness under our Credit Agreement. In order to manage this exposure, we have entered into an interest rate swap agreement to hedge the variability of cash flows associated with such interest obligations. The interest rate swap is designated as a cash flow hedge, which effectively fixes the interest rate on the hedged indebtedness under our Credit Agreement at 3.06%. At March 31, 2020 and December 28, 2019, this swap was in a net liability position with an aggregate fair value of $42 million and $17 million, respectively; which is presented in our condensed consolidated balance sheets in other current liabilities . Series 2020-A Senior Notes In March 2020, we issued $300 million aggregate principal amount of 2.50% senior unsecured Series 2020-A notes (the "Series 2020-A Notes") due March 11, 2030; pursuant to the Master Note Agreement (the "2019 Shelf Agreement") we entered into in November 2019. Interest on the Series 2020-A Notes is payable semiannually on each March 11 and September 11, commencing September 11, 2020, and the principal balance is due at maturity. The Company may prepay at any time all, or any part of, the outstanding principal amount of the Series 2020-A Notes, subject to the payment of a make-whole amount. The Series 2020-A Notes are subject to the terms of the 2019 Shelf Agreement, which contains customary events of default and covenants related to limitations on indebtedness and transactions with affiliates and the maintenance of certain financial ratios. As of March 31, 2020, $750 million remains available for sale under the 2019 Shelf Agreement, which is uncommitted and subject to participation by the Purchasers.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements We determine fair value measurements used in our consolidated financial statements based upon the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: • Level 1 – Valuations based on quoted prices in active markets for identical assets or liabilities that the entity has the ability to access. • Level 2 – Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. • Level 3 – Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The following table details our financial assets measured and recorded at fair value on a recurring basis at March 31, 2020: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 149,756 $ — $ — Time deposits Cash equivalents — 60,614 — Time deposits Short-term investments — 14,737 — Commercial paper Short-term investments — 4,974 — Government and corporate bonds Short-term investments — 79,063 — Government and corporate bonds Long-term investments — 85,389 — The following table details our financial assets measured and recorded at fair value on a recurring basis at December 28, 2019: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 185,666 $ — $ — Time deposits Cash equivalents — 64,286 — Time deposits Short-term investments — 2,506 — Government and corporate bonds Short-term investments — 83,313 — Government and corporate bonds Long-term investments — 96,210 — Our interest rate swap agreement is measured and recorded at fair value on a recurring basis using a Level 2 valuation. The fair value of such agreement is based on the market standard methodology of netting the discounted expected future variable cash receipts and the discounted future fixed cash payments. The variable cash receipts are based on an expectation of future interest rates derived from observed market interest rate forward curves. Since these inputs are observable in active markets over the terms that the instrument is held, the derivative is classified as Level 2 in the hierarchy. We estimate the fair value of our long-term, fixed rate debt using a Level 3 discounted cash flow analysis based on current borrowing rates for debt with similar maturities. We estimate the fair value of our long-term, variable rate debt using a Level 3 discounted cash flow analysis based on LIBOR rate forward curves. The fair value of our long-term debt at March 31, 2020 and December 28, 2019 was approximately $1.35 billion and $1.07 billion, respectively. The carrying amount of such debt at March 31, 2020 and December 28, 2019 was $1.33 billion and $1.03 billion, respectively.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesWe determine the tax provision for interim periods using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter we update our estimate of the annual effective tax rate, and if our estimated tax rate changes, we make a cumulative adjustment. Our effective tax rate was 20.0% and 19.5% for the first three months of 2020 and 2019, respectively.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share A reconciliation of the numerators and the denominators of the basic and diluted per share computations are as follows: Three Months Ended 2020 2019 Earnings Shares Per-Share Earnings Shares Per-Share (In thousands, except per share data) (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount Basic earnings per share: Income available to common shareholders $ 147,159 309,657 $ 0.48 $ 166,219 324,573 $ 0.51 Effect of dilutive securities: Stock options, non-vested shares and share units — 2,583 — 2,430 Diluted earnings per share: Income available to common shareholders including assumed conversions $ 147,159 312,240 $ 0.47 $ 166,219 327,003 $ 0.51 For the three months ended March 31, 2020 and March 30, 2019, options to purchase 4.1 million and 13.7 million shares of common stock at per share prices ranging from $56.76 to $76.49 and $47.99 to $73.40, respectively, were outstanding but were not included in the computation of diluted earnings per share because they were anti-dilutive.

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Shareholders' Equity and Share-based Payments	Share-Based Compensation and Equity Stock Options Stock option activity for the three months ended March 31, 2020 was as follows: (In thousands, except per share and term data) Number of Weighted- Aggregate Weighted-Average Outstanding at beginning of year 15,416 $ 56.36 Granted 2 73.01 Exercised (2,449) 48.43 Forfeited and expired (152) 61.55 Outstanding as of March 31, 2020 12,817 57.82 $ 83,254 6.08 Exercisable as of March 31, 2020 6,269 $ 54.59 $ 61,354 4.55 The weighted-average assumptions used to estimate the fair value, under the Black-Scholes-Merton pricing model, of stock options granted during the three months ended March 31, 2020 were as follows: Expected volatility (%) 24.5 % Expected dividend rate (%) 1 % Expected term (yrs) 6 Risk-free rate (%) 1.5 % Fair value per option $ 17.53 As of March 31, 2020, there was $79 million of total unrecognized compensation cost related to stock options granted under all plans. That cost is expected to be recognized over a weighted-average period of 2.52 years. Non-vested Shares and Share Units Non-vested share and share unit activity for the three months ended March 31, 2020 was as follows: (In thousands, except per share data) Number of Shares Weighted-Average Outstanding at beginning of year 2,634 $ 65.30 Granted 43 72.28 Vested (157) 64.01 Forfeited (22) 65.49 Outstanding as of March 31, 2020 2,498 $ 65.50 As of March 31, 2020, there was $108 million of total unrecognized compensation cost related to non-vested share and share unit awards granted under all plans. That cost is expected to be recognized over a weighted-average period of 1.88 years. Share-Based Compensation Cost The following table presents total compensation expense recognized with respect to stock options, non-vested shares and share units, and our associate stock purchase plan: Three Months Ended (In thousands) 2020 2019 Stock option and non-vested share and share unit compensation expense $ 35,031 $ 19,860 Associate stock purchase plan expense 1,101 1,542 Amounts capitalized in software development costs, net of amortization (745) 187 Amounts charged against earnings, before income tax benefit $ 35,387 $ 21,589 Amount of related income tax benefit recognized in earnings $ 6,443 $ 4,201 Treasury Stock Under our current share repurchase program, which was initially approved by our Board of Directors in May 2017 and most recently amended in December 2019, the Company is authorized to repurchase up to $3.70 billion of shares of our common stock, excluding transaction costs. The repurchases are to be effectuated in the open market, by block purchase, in privately negotiated transactions, or through other transactions managed by broker-dealers. No time limit was set for the completion of the program. During the three months ended March 31, 2020, we repurchased 9.2 million shares for total consideration of $650 million under the program. The shares were recorded as treasury stock and accounted for under the cost method. No repurchased shares have been retired. As of March 31, 2020, $1.03 billion remains available for repurchase under the program. Dividends On March 19, 2020, our Board of Directors declared a cash dividend of $0.18 per share on our issued and outstanding common stock, which was paid on April 17, 2020 to shareholders of record as of April 3, 2020. In connection with the declaration of such dividend, our non-vested shares and share units are entitled to dividend equivalents, which will be payable to the holder subject to, and upon vesting of, the underlying awards. Our outstanding stock options are not entitled to dividend or dividend equivalents. At March 31, 2020, our condensed consolidated balance sheet included a liability for dividends payable of $55 million, which is included in other current liabilities. Accumulated Other Comprehensive Loss, Net (AOCI) The components of AOCI, net of tax, were as follows: Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 28, 2019 $ (106,347) $ (12,578) $ 265 $ (118,660) Other comprehensive income (loss) before reclassifications (20,546) (20,430) (849) (41,825) Amounts reclassified from AOCI — 1,122 — 1,122 Balance at March 31, 2020 $ (126,893) $ (31,886) $ (584) $ (159,363) Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 29, 2018 $ (102,939) $ — $ (613) $ (103,552) Other comprehensive income (loss) before reclassifications 2,321 — 637 2,958 Amounts reclassified from AOCI — — — — Balance at March 30, 2019 $ (100,618) $ — $ 24 $ (100,594) The effects on net earnings of amounts reclassified from AOCI were as follows: (In thousands) Three Months Ended AOCI Component Location 2020 2019 Unrealized loss on cash flow hedge Other income, net $ (1,372) $ — Income taxes 250 — Total amount reclassified, net of tax $ (1,122) $ —

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies Disclosure	Contingencies We accrue estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450,  Contingencies  ("ASC 450"). No less than quarterly, we review the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. Should any one or a combination of more than one of these proceedings be successful, or should we determine to settle any one or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction or be forced to change the manner in which we operate our business, which could have a material adverse impact on our business, results of operations, cash flows or financial condition. As previously disclosed, we continue to be in dispute with Fujitsu Services Limited ("Fujitsu") regarding Fujitsu's obligation to pay amounts to us due upon the termination of a subcontract, including client receivables, in connection with Fujitsu's contract as the prime contractor in the National Health Service ("NHS") initiative to automate clinical processes and digitize medical records in the Southern region of England. The NHS terminated its contract with Fujitsu, which gave rise to the termination of our subcontract with Fujitsu. We filed a request for arbitration with the London Court of International Arbitration on April 22, 2019 seeking damages. On December 30, 2019, Fujitsu filed its Defense and Counterclaim (the "Counterclaim") in response. In its Counterclaim, Fujitsu defends against our claim in full and argues that we are liable to Fujitsu for: (i) £306 million in damages based on our alleged fraudulent misrepresentations inducing Fujitsu to enter into the subcontract; or (ii) alternatively, £173.8 million in damages based on our alleged breaches of the subcontract. We believe that Fujitsu's claims are without merit and will vigorously defend against them, and we continue to believe that we have valid and equitable grounds for recovery of the disputed client receivables; however, there can be no assurances as to the outcome of the dispute. As previously disclosed, we recorded a pre-tax charge of $45 million in the fourth quarter of 2018 to provide an allowance against the disputed client receivables reflecting the uncertainty in collection of such receivables and related litigation risk resulting from the conclusion of the non-binding alternative dispute resolution procedures, which occurred before we filed our request for arbitration. We have not concluded that a loss related to the new claims raised by Fujitsu in the Counterclaim is probable, nor have we accrued a liability related to these claims beyond the previously reported pre-tax charge recorded in the fourth quarter of 2018. Although we believe a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss with respect to the Counterclaim given that the dispute is in the early stages of the arbitration process. Cerner Health Services, Inc. ("Cerner HS"), a wholly owned subsidiary of Cerner Corporation, filed a lawsuit in the Chester County, Pennsylvania, Court of Common Pleas against NextGen Healthcare Information Systems, LLC ("NextGen") relating to a dispute arising out of a supplier relationship initially established between Siemens Health Services, Inc. and NextGen prior to the acquisition of the assets of Siemens Health Services, Inc. by Cerner HS in 2015. In September 2017, the court issued a preliminary injunction to prevent NextGen from refusing to honor certain contractual obligations to support Cerner HS's clients who use NextGen ambulatory EHR solutions. In September 2018, NextGen filed a counterclaim alleging breach of contract and tortious interference but did not specify its damages. In August 2019, NextGen provided an expert report alleging profit disgorgement damages of $135 million or, alternatively, $30.5 million in lost profit damages, but the report did not discuss how our actions allegedly caused NextGen's damages. In December 2019, we deposed NextGen's expert, gaining additional clarity on categories of alleged damages but not on the alleged theories of liability. A jury trial is set to begin on January 25, 2021. We believe NextGen's claims are without merit and will vigorously defend against them; however, there can be no assurances as to the outcome of the dispute. We have not concluded that a loss related to the claims raised by NextGen in its counterclaim is probable, nor have we accrued a liability related to these claims. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss in light of the inherent difficulty of predicting the outcome of litigation generally, the wide range of damages presented by NextGen's expert, and the continued lack of clarity on the causal connection between Cerner Corporation's and Cerner HS's actions and any alleged damages. On April 4, 2018, Ruby L. Lowe, Guardian ad Litem for Michael A. Taylor, filed a lawsuit against Cerner Corporation in the Circuit Court for Clarke County, Virginia. On November 4, 2019, the Court substituted Cerner HS in place of Cerner Corporation as the defendant in the lawsuit. Plaintiff asserts claims of negligent product liability, negligence, and violations of the Virginia Consumer Protection Act. Plaintiff alleges that Mr. Taylor suffered injuries following his medical treatment at Virginia Hospital Center, a client of Cerner HS. Specifically, plaintiff asserts a software defect contributed to an order to monitor pulse oxygen not starting until a day after it was ordered, allegedly contributing to Taylor's injury. Plaintiff seeks an award of $50 million. A jury trial is set to begin on September 8, 2020. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss in light of the inherent difficulty of predicting the outcome of litigation generally, the wide range of damages presented by plaintiff, and the difficulty plaintiff will have proving that the solution was the proximate cause of plaintiff's harm. The terms of our agreements with our clients generally provide for limited indemnification of such clients against losses, expenses and liabilities arising from third party or other claims based on, among other things, alleged infringement by our solutions of an intellectual property right of third parties or damages caused by data privacy breaches or system interruptions. The terms of such indemnification often limit the scope of and remedies for such indemnification obligations and generally include, as applicable, a right to replace or modify an infringing solution. For several reasons, including the lack of a sufficient number of prior indemnification claims relating to IP infringement, data privacy breaches or system interruptions, the inherent uncertainty stemming from such claims, and the lack of a monetary liability limit for such claims under the terms of the corresponding agreements with our clients, we cannot determine the maximum amount of potential future payments, if any, related to such indemnification provisions. In addition to commitments and obligations in the ordinary course of business, we are involved in various other legal proceedings and claims that arise in the ordinary course of business, including for example, employment and client disputes and litigation alleging solution and implementation defects, personal injury, intellectual property infringement, violations of law and breaches of contract and warranties. Many of these proceedings are at preliminary stages and many seek an indeterminate amount of damages. At this time, we do not believe the range of potential losses under such claims to be material to our consolidated financial statements.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting We have two operating segments, Domestic and International. Revenues are derived primarily from the sale of clinical, financial and administrative information solutions and services. The cost of revenues includes the cost of third-party consulting services, computer hardware, devices and sublicensed software purchased from manufacturers for delivery to clients. It also includes the cost of hardware maintenance and sublicensed software support subcontracted to the manufacturers. Operating expenses incurred by the geographic business segments consist of sales and client service expenses including salaries of sales and client service personnel, expenses associated with our managed services business, marketing expenses, communications expenses and unreimbursed travel expenses. "Other" includes expenses that have not been allocated to the operating segments, such as software development, general and administrative expenses, certain organizational restructuring and other expense, share-based compensation expense, and certain amortization and depreciation. Performance of the segments is assessed at the operating earnings level by our chief operating decision maker, who is our Chief Executive Officer. Items such as interest, income taxes, capital expenditures and total assets are managed at the consolidated level and thus are not included in our operating segment disclosures. Accounting policies for each of the reportable segments are the same as those used on a consolidated basis. The following table presents a summary of our operating segments and other expense for the three months ended March 31, 2020 and March 30, 2019: (In thousands) Domestic International Other Total Three Months Ended 2020 Revenues $ 1,246,415 $ 165,326 $ — $ 1,411,741 Costs of revenue 228,567 25,849 — 254,416 Operating expenses 570,094 66,555 342,300 978,949 Total costs and expenses 798,661 92,404 342,300 1,233,365 Operating earnings (loss) $ 447,754 $ 72,922 $ (342,300) $ 178,376 (In thousands) Domestic International Other Total Three Months Ended 2019 Revenues $ 1,230,830 $ 159,047 $ — $ 1,389,877 Costs of revenue 228,559 24,645 — 253,204 Operating expenses 572,018 68,169 298,542 938,729 Total costs and expenses 800,577 92,814 298,542 1,191,933 Operating earnings (loss) $ 430,253 $ 66,233 $ (298,542) $ 197,944

Organization, Consolidation and

Organization, Consolidation and Presentation of Financial Statements (Policies)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting, Policy [Policy Text Block]	The condensed consolidated financial statements were prepared using GAAP
Fiscal Period, Policy [Policy Text Block]	Prior to fiscal year 2020, our first fiscal quarter ended on the Saturday closest to March 31. The first quarter of 2019 consisted of 91 days and ended on March 30, 2019. In December 2019, our Board of Directors approved the change of our fiscal year to a calendar year, commencing with fiscal year 2020. Accordingly, our 2020 first fiscal quarter was extended and ran from December 29, 2019 to March 31, 2020; consisting of 94 days. All references to periods in these notes to condensed consolidated financial statements represent the respective periods described above ending on March 31, 2020 and March 30, 2019, unless otherwise noted.

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	The following table presents revenues disaggregated by our business models: Three Months Ended 2020 2019 (In thousands) Domestic International Total Domestic International Total Licensed software $ 146,497 $ 11,535 $ 158,032 $ 140,445 $ 14,032 $ 154,477 Technology resale 44,449 7,038 51,487 49,158 6,382 55,540 Subscriptions 86,936 7,449 94,385 77,702 6,589 84,291 Professional services 452,784 58,562 511,346 437,229 53,210 490,439 Managed services 279,736 29,618 309,354 277,325 27,068 304,393 Support and maintenance 223,416 50,265 273,681 226,481 50,482 276,963 Reimbursed travel 12,597 859 13,456 22,490 1,284 23,774 Total revenues $ 1,246,415 $ 165,326 $ 1,411,741 $ 1,230,830 $ 159,047 $ 1,389,877 The following table presents our revenues disaggregated by timing of revenue recognition: Three Months Ended 2020 2019 (In thousands) Domestic International Total Domestic International Total Revenue recognized over time $ 1,165,515 $ 153,444 $ 1,318,959 $ 1,135,982 $ 142,211 $ 1,278,193 Revenue recognized at a point in time 80,900 11,882 92,782 94,848 16,836 111,684 Total revenues $ 1,246,415 $ 165,326 $ 1,411,741 $ 1,230,830 $ 159,047 $ 1,389,877

Receivables (Tables)

Receivables (Tables)	3 Months Ended
	Mar. 31, 2020
Receivables [Abstract]
Summary of Net Receivables	A summary of net receivables is as follows: (In thousands) March 31, 2020 December 28, 2019 Client receivables $ 1,274,158 $ 1,245,670 Less: Allowance for doubtful accounts 123,130 106,075 Total receivables, net $ 1,151,028 $ 1,139,595
Accounts Receivable, Allowance for Credit Loss	A reconciliation of the beginning and ending amount of our allowance for doubtful accounts is as follows: (In thousands) Allowance for doubtful accounts - balance at December 28, 2019 $ 106,075 Cumulative effect of accounting change (ASU 2016-13) 4,606 Additions charged to costs and expenses 15,678 Deductions (3,229) Allowance for doubtful accounts - balance at March 31, 2020 $ 123,130
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	A summary of such cumulative effect adjustment is as follows: (In thousands) Increase/(Decrease) Receivables, net $ (4,606) Retained earnings (4,606)

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2020
Investments [Abstract]
Schedule of available-for-sale investments	Available-for-sale investments at March 31, 2020 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 149,756 $ — $ — $ 149,756 Time deposits 60,614 — — 60,614 Total cash equivalents 210,370 — — 210,370 Short-term investments: Time deposits 14,737 — — 14,737 Commercial paper 5,000 — (26) 4,974 Government and corporate bonds 79,298 69 (304) 79,063 Total short-term investments 99,035 69 (330) 98,774 Long-term investments: Government and corporate bonds 86,192 50 (853) 85,389 Total available-for-sale investments $ 395,597 $ 119 $ (1,183) $ 394,533 Available-for-sale investments at December 28, 2019 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 185,666 $ — $ — $ 185,666 Time deposits 64,286 — — 64,286 Total cash equivalents 249,952 — — 249,952 Short-term investments: Time deposits 2,506 — — 2,506 Government and corporate bonds 83,272 52 (11) 83,313 Total short-term investments 85,778 52 (11) 85,819 Long-term investments: Government and corporate bonds 96,186 91 (67) 96,210 Total available-for-sale investments $ 431,916 $ 143 $ (78) $ 431,981

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Schedule of Debt	The following is a summary of indebtedness outstanding: (In thousands) March 31, 2020 December 28, 2019 Credit agreement loans due May 5, 2024 $ 600,000 $ 600,000 Senior notes: Series 2020-A due March 11, 2030 300,000 — Series 2015-A due February 15, 2022 225,000 225,000 Series 2015-B due February 14, 2025 200,000 200,000 Other 14,162 14,162 Total indebtedness 1,339,162 1,039,162 Less: debt issuance costs (745) (780) Long-term debt $ 1,338,417 $ 1,038,382

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table details our financial assets measured and recorded at fair value on a recurring basis at March 31, 2020: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 149,756 $ — $ — Time deposits Cash equivalents — 60,614 — Time deposits Short-term investments — 14,737 — Commercial paper Short-term investments — 4,974 — Government and corporate bonds Short-term investments — 79,063 — Government and corporate bonds Long-term investments — 85,389 — The following table details our financial assets measured and recorded at fair value on a recurring basis at December 28, 2019: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 185,666 $ — $ — Time deposits Cash equivalents — 64,286 — Time deposits Short-term investments — 2,506 — Government and corporate bonds Short-term investments — 83,313 — Government and corporate bonds Long-term investments — 96,210 —

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Reconciliation Of The Numerators And The Denominators Of The Basic And Diluted Per Share	A reconciliation of the numerators and the denominators of the basic and diluted per share computations are as follows: Three Months Ended 2020 2019 Earnings Shares Per-Share Earnings Shares Per-Share (In thousands, except per share data) (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount Basic earnings per share: Income available to common shareholders $ 147,159 309,657 $ 0.48 $ 166,219 324,573 $ 0.51 Effect of dilutive securities: Stock options, non-vested shares and share units — 2,583 — 2,430 Diluted earnings per share: Income available to common shareholders including assumed conversions $ 147,159 312,240 $ 0.47 $ 166,219 327,003 $ 0.51

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule Of Stock Options Activity	Stock option activity for the three months ended March 31, 2020 was as follows: (In thousands, except per share and term data) Number of Weighted- Aggregate Weighted-Average Outstanding at beginning of year 15,416 $ 56.36 Granted 2 73.01 Exercised (2,449) 48.43 Forfeited and expired (152) 61.55 Outstanding as of March 31, 2020 12,817 57.82 $ 83,254 6.08 Exercisable as of March 31, 2020 6,269 $ 54.59 $ 61,354 4.55
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The weighted-average assumptions used to estimate the fair value, under the Black-Scholes-Merton pricing model, of stock options granted during the three months ended March 31, 2020 were as follows: Expected volatility (%) 24.5 % Expected dividend rate (%) 1 % Expected term (yrs) 6 Risk-free rate (%) 1.5 % Fair value per option $ 17.53
Schedule of Share-based Compensation, Restricted Stock Activity	Non-vested share and share unit activity for the three months ended March 31, 2020 was as follows: (In thousands, except per share data) Number of Shares Weighted-Average Outstanding at beginning of year 2,634 $ 65.30 Granted 43 72.28 Vested (157) 64.01 Forfeited (22) 65.49 Outstanding as of March 31, 2020 2,498 $ 65.50
Compensation Expense Recognized In The Condensed Consolidated Statements Of Operations	The following table presents total compensation expense recognized with respect to stock options, non-vested shares and share units, and our associate stock purchase plan: Three Months Ended (In thousands) 2020 2019 Stock option and non-vested share and share unit compensation expense $ 35,031 $ 19,860 Associate stock purchase plan expense 1,101 1,542 Amounts capitalized in software development costs, net of amortization (745) 187 Amounts charged against earnings, before income tax benefit $ 35,387 $ 21,589 Amount of related income tax benefit recognized in earnings $ 6,443 $ 4,201
Schedule of Accumulated Other Comprehensive Income (Loss)	The components of AOCI, net of tax, were as follows: Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 28, 2019 $ (106,347) $ (12,578) $ 265 $ (118,660) Other comprehensive income (loss) before reclassifications (20,546) (20,430) (849) (41,825) Amounts reclassified from AOCI — 1,122 — 1,122 Balance at March 31, 2020 $ (126,893) $ (31,886) $ (584) $ (159,363) Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 29, 2018 $ (102,939) $ — $ (613) $ (103,552) Other comprehensive income (loss) before reclassifications 2,321 — 637 2,958 Amounts reclassified from AOCI — — — — Balance at March 30, 2019 $ (100,618) $ — $ 24 $ (100,594)
Reclassification out of Accumulated Other Comprehensive Income	The effects on net earnings of amounts reclassified from AOCI were as follows: (In thousands) Three Months Ended AOCI Component Location 2020 2019 Unrealized loss on cash flow hedge Other income, net $ (1,372) $ — Income taxes 250 — Total amount reclassified, net of tax $ (1,122) $ —

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Summary of the Operating Information	The following table presents a summary of our operating segments and other expense for the three months ended March 31, 2020 and March 30, 2019: (In thousands) Domestic International Other Total Three Months Ended 2020 Revenues $ 1,246,415 $ 165,326 $ — $ 1,411,741 Costs of revenue 228,567 25,849 — 254,416 Operating expenses 570,094 66,555 342,300 978,949 Total costs and expenses 798,661 92,404 342,300 1,233,365 Operating earnings (loss) $ 447,754 $ 72,922 $ (342,300) $ 178,376 (In thousands) Domestic International Other Total Three Months Ended 2019 Revenues $ 1,230,830 $ 159,047 $ — $ 1,389,877 Costs of revenue 228,559 24,645 — 253,204 Operating expenses 572,018 68,169 298,542 938,729 Total costs and expenses 800,577 92,814 298,542 1,191,933 Operating earnings (loss) $ 430,253 $ 66,233 $ (298,542) $ 197,944

Policies (Details)

Policies (Details)	3 Months Ended
	Mar. 31, 2020
Interim Statement Presentation [Line Items]
Basis of Accounting, Policy [Policy Text Block]	The condensed consolidated financial statements were prepared using GAAP
Use of Estimates, Policy [Policy Text Block]	These principles require us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses
Fiscal Period, Policy [Policy Text Block]	Prior to fiscal year 2020, our first fiscal quarter ended on the Saturday closest to March 31. The first quarter of 2019 consisted of 91 days and ended on March 30, 2019. In December 2019, our Board of Directors approved the change of our fiscal year to a calendar year, commencing with fiscal year 2020. Accordingly, our 2020 first fiscal quarter was extended and ran from December 29, 2019 to March 31, 2020; consisting of 94 days. All references to periods in these notes to condensed consolidated financial statements represent the respective periods described above ending on March 31, 2020 and March 30, 2019, unless otherwise noted.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform, such as the upcoming discontinuance of the London Interbank Offered Rate ("LIBOR"). The accommodations within ASU 2020-04 may be applied prospectively from the beginning of our 2020 first quarter through December 31, 2022. We are currently evaluating the effect that ASU 2020-04 may have on our contracts that reference LIBOR, specifically, our Third Amended and Restated Credit Agreement (as amended, the "Credit Agreement") and related interest rate swap. As of the date of this filing, we have not elected to apply any of the provisions of this standard.
Accounting Standards Update 2018-18 [Member]
Interim Statement Presentation [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Description	In November 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which clarifies when transactions between participants in a collaborative arrangement are within the scope of the FASB's recent revenue standard (Topic 606). Such guidance clarifies revenue recognition and financial statement presentation for transactions between collaboration participants. We adopted ASU 2018-18 in the first quarter of 2020. Such guidance did not have an impact on our consolidated financial statements and related disclosures.

Disaggregation of Revenue (Deta

Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 30, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 1,411,741	$ 1,389,877
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,318,959	1,278,193
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenues	92,782	111,684
Domestic Segment
Disaggregation of Revenue [Line Items]
Revenues	1,246,415	1,230,830
Domestic Segment | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,165,515	1,135,982
Domestic Segment | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenues	80,900	94,848
International Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	165,326	159,047
International Segment [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenues	153,444	142,211
International Segment [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenues	11,882	16,836
Sales Revenue, Licensed Software, Net [Member]
Disaggregation of Revenue [Line Items]
Revenues	158,032	154,477
Sales Revenue, Licensed Software, Net [Member] | Domestic Segment
Disaggregation of Revenue [Line Items]
Revenues	146,497	140,445
Sales Revenue, Licensed Software, Net [Member] | International Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	11,535	14,032
Sales Revenue, Technology Resale, Net [Member]
Disaggregation of Revenue [Line Items]
Revenues	51,487	55,540
Sales Revenue, Technology Resale, Net [Member] | Domestic Segment
Disaggregation of Revenue [Line Items]
Revenues	44,449	49,158
Sales Revenue, Technology Resale, Net [Member] | International Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	7,038	6,382
Sales Revenue, Subscriptions, Net [Member]
Disaggregation of Revenue [Line Items]
Revenues	94,385	84,291
Sales Revenue, Subscriptions, Net [Member] | Domestic Segment
Disaggregation of Revenue [Line Items]
Revenues	86,936	77,702
Sales Revenue, Subscriptions, Net [Member] | International Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	7,449	6,589
Sales Revenue, Professional Services, Net [Member]
Disaggregation of Revenue [Line Items]
Revenues	511,346	490,439
Sales Revenue, Professional Services, Net [Member] | Domestic Segment
Disaggregation of Revenue [Line Items]
Revenues	452,784	437,229
Sales Revenue, Professional Services, Net [Member] | International Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	58,562	53,210
Sales Revenue, Managed Services, Net [Member]
Disaggregation of Revenue [Line Items]
Revenues	309,354	304,393
Sales Revenue, Managed Services, Net [Member] | Domestic Segment
Disaggregation of Revenue [Line Items]
Revenues	279,736	277,325
Sales Revenue, Managed Services, Net [Member] | International Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	29,618	27,068
Sales Revenue, Support and Maintenance Services, Net [Member]
Disaggregation of Revenue [Line Items]
Revenues	273,681	276,963
Sales Revenue, Support and Maintenance Services, Net [Member] | Domestic Segment
Disaggregation of Revenue [Line Items]
Revenues	223,416	226,481
Sales Revenue, Support and Maintenance Services, Net [Member] | International Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	50,265	50,482
Sales Revenue, Reimbursement Revenue [Member]
Disaggregation of Revenue [Line Items]
Revenues	13,456	23,774
Sales Revenue, Reimbursement Revenue [Member] | Domestic Segment
Disaggregation of Revenue [Line Items]
Revenues	12,597	22,490
Sales Revenue, Reimbursement Revenue [Member] | International Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 859	$ 1,284

Performance Obligation (Details

Performance Obligation (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)
Revenue Recognition [Line Items]
Revenue, Remaining Performance Obligation	$ 13,470
Contract with Customer, Liability, Revenue Recognized	$ 128
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation	we expect to recognize approximately 30% of the revenue over the next 12 months and the remainder thereafter

Revenue from Contracts with C_3

Revenue from Contracts with Customers (Details)	3 Months Ended
	Mar. 31, 2020	Mar. 30, 2019
Revenue from Contract with Customer [Abstract]
Segment Reporting, Disclosure of Major Customers	17	10

Receivables (Narrative) (Detail

Receivables (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 30, 2019
Receivables [Abstract]
Client cash collections	$ 1,370	$ 1,360
Accounting Standards Update 2016-13 [Member]
Receivables [Abstract]
New Accounting Pronouncement or Change in Accounting Principle, Description	In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which provides a new impairment model for certain financial assets that is based on expected losses rather than incurred losses. Such guidance impacts how we determine our allowance for estimated uncollectible client receivables. The standard requires use of the modified retrospective (cumulative effect) transition approach as of the beginning of the first reporting period in which the guidance was effective, which for the Company was the first quarter of 2020. Under this transition method, the cumulative effect from prior periods upon applying this new guidance was recognized in our condensed consolidated balance sheets as of December 29, 2019. We did not recast comparative periods.
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Description	In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which provides a new impairment model for certain financial assets that is based on expected losses rather than incurred losses. Such guidance impacts how we determine our allowance for estimated uncollectible client receivables. The standard requires use of the modified retrospective (cumulative effect) transition approach as of the beginning of the first reporting period in which the guidance was effective, which for the Company was the first quarter of 2020. Under this transition method, the cumulative effect from prior periods upon applying this new guidance was recognized in our condensed consolidated balance sheets as of December 29, 2019. We did not recast comparative periods.

Receivables (Summary Of Net Rec

Receivables (Summary Of Net Receivables) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 28, 2019
Receivables [Abstract]
Gross accounts receivable	$ 1,274,158	$ 1,245,670
Less: Allowance for doubtful accounts	123,130	106,075
Total receivables, net	$ 1,151,028	$ 1,139,595

Schedule of Valuation and Quali

Schedule of Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 28, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Accounts Receivable, Credit Loss Expense (Reversal)	$ 15,678
Accounts Receivable, Allowance for Credit Loss, Writeoff	3,229
Accounts Receivable, Allowance for Credit Loss	123,130	$ 106,075
Accounting Standards Update 2016-13 [Member] | Cumulative Effect, Period of Adoption, Adjustment
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment	$ 4,606

Cumulative Effect Transition (D

Cumulative Effect Transition (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 28, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained Earnings	$ 6,022,256	$ 5,934,909
Receivables, Net	$ 1,151,028	1,139,595
Accounting Standards Update 2016-13 [Member] | Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained Earnings		(4,606)
Receivables, Net		$ (4,606)

Investments (Narrative) (Detail

Investments (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 28, 2019
Investments [Abstract]
Proceeds from Sale of Available-for-sale Securities	$ 5
Equity Securities without Readily Determinable Fair Value, Amount	$ 315	$ 314

Investments (Details)

Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 28, 2019
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	$ 395,597	$ 431,916
Gross Unrealized Gains	119	143
Gross Unrealized Losses	(1,183)	(78)
Debt Securities, Available-for-sale	394,533	431,981
Cash equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	210,370	249,952
Debt Securities, Available-for-sale	210,370	249,952
Cash equivalents [Member] | Money market funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	149,756	185,666
Debt Securities, Available-for-sale	149,756	185,666
Cash equivalents [Member] | Time deposits [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	60,614	64,286
Debt Securities, Available-for-sale	60,614	64,286
Short-term investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	99,035	85,778
Gross Unrealized Gains	69	52
Gross Unrealized Losses	(330)	(11)
Debt Securities, Available-for-sale	98,774	85,819
Short-term investments [Member] | Time deposits [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	14,737	2,506
Debt Securities, Available-for-sale	14,737	2,506
Short-term investments [Member] | Commercial paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	5,000
Gross Unrealized Losses	(26)
Debt Securities, Available-for-sale	4,974
Short-term investments [Member] | Government and corporate bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	79,298	83,272
Gross Unrealized Gains	69	52
Gross Unrealized Losses	(304)	(11)
Debt Securities, Available-for-sale	79,063	83,313
Long-term investments [Member] | Government and corporate bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	86,192	96,186
Gross Unrealized Gains	50	91
Gross Unrealized Losses	(853)	(67)
Debt Securities, Available-for-sale	$ 85,389	$ 96,210

Schedule of Indebtedness Outsta

Schedule of Indebtedness Outstanding (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 28, 2019
Debt Instrument [Line Items]
Carrying amount of long-term debt	$ 1,339,162	$ 1,039,162
Debt Issuance Costs, Noncurrent, Net	745	780
Long-term Debt	1,338,417	1,038,382
Line of Credit
Debt Instrument [Line Items]
Carrying amount of long-term debt	$ 600,000	600,000
Debt Instrument, Maturity Date	May 5, 2024
Senior Notes - Series 20-A due March 11, 2030
Debt Instrument [Line Items]
Carrying amount of long-term debt	$ 300,000	0
Debt Instrument, Maturity Date	Mar. 11, 2030
Senior Notes - Series 2015 A due February 15, 2022
Debt Instrument [Line Items]
Carrying amount of long-term debt	$ 225,000	225,000
Debt Instrument, Maturity Date	Feb. 15, 2022
Senior Notes - Series 2015-B due February 14, 2025
Debt Instrument [Line Items]
Carrying amount of long-term debt	$ 200,000	200,000
Debt Instrument, Maturity Date	Feb. 14, 2025
Other
Debt Instrument [Line Items]
Carrying amount of long-term debt	$ 14,162	$ 14,162

Indebtedness (Narrative) (Detai

Indebtedness (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 28, 2019
Debt Instrument [Line Items]
Line of Credit Facility, Interest Rate at Period End	1.60%
General Discussion of Derivative Instruments and Hedging Activities	We are exposed to market risk from fluctuations in the variable interest rates on outstanding indebtedness under our Credit Agreement. In order to manage this exposure, we have entered into an interest rate swap agreement to hedge the variability of cash flows associated with such interest obligations. The interest rate swap is designated as a cash flow hedge, which effectively fixes the interest rate on the hedged indebtedness under our Credit Agreement at 3.06%
Derivative, Fair Value, Net	$ 42	$ 17
Debt Instrument, Amount Uncommitted and Available for Sale	750
Senior Notes - Series 20-A due March 11, 2030
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 300
Debt Instrument, Interest Rate, Stated Percentage	2.50%
Debt Instrument, Maturity Date	Mar. 11, 2030
Debt Instrument, Frequency of Periodic Payment	payable semiannually
Debt Instrument, Date of First Required Payment	Sep. 11, 2020
Debt Instrument, Restrictive Covenants	The Series 2020-A Notes are subject to the terms of the 2019 Shelf Agreement, which contains customary events of default and covenants related to limitations on indebtedness and transactions with affiliates and the maintenance of certain financial ratios.

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 28, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements, Valuation Processes, Description	We estimate the fair value of our long-term, fixed rate debt using a Level 3 discounted cash flow analysis based on current borrowing rates for debt with similar maturities. We estimate the fair value of our long-term, variable rate debt using a Level 3 discounted cash flow analysis based on LIBOR rate forward curves.
Fair value of long-term debt, including current maturities	$ 1,350	$ 1,070
Unsecured Long-term Debt, Noncurrent	$ 1,330	$ 1,030

Fair Value Measurements Fair Va

Fair Value Measurements Fair Value, Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 28, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	$ 394,533	$ 431,981
Level 1 [Member] | Money market funds [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	149,756	185,666
Level 2 [Member] | Time deposits [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	60,614	64,286
Short-term investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	98,774	85,819
Short-term investments [Member] | Level 2 [Member] | Time deposits [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	14,737	2,506
Short-term investments [Member] | Level 2 [Member] | Commercial paper [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	4,974
Short-term investments [Member] | Level 2 [Member] | Government and corporate bonds [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	79,063	83,313
Long-term investments [Member] | Level 2 [Member] | Government and corporate bonds [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	$ 85,389	$ 96,210

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended
	Mar. 31, 2020	Mar. 30, 2019
Income Tax Disclosure [Abstract]
Effective tax rate	20.00%	19.50%

Earnings Per Share (Reconciliat

Earnings Per Share (Reconciliation Of The Numerators And The Denominators Of The Basic And Diluted Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 30, 2019
Earnings Per Share [Abstract]
Income available to common shareholders, basic	$ 147,159	$ 166,219
Income available to common shareholders including assumed conversions, diluted	$ 147,159	$ 166,219
Basic weighted average shares outstanding	309,657	324,573
Stock options and non-vested shares, incremental shares	2,583	2,430
Diluted weighted average shares outstanding	312,240	327,003
Basic earnings per share	$ 0.48	$ 0.51
Diluted earnings per share	$ 0.47	$ 0.51

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - $ / shares shares in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 30, 2019
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share, amount	4.1	13.7
Antidilutive securities excluded from computation of earnings per share, exercise price, lower range limit	$ 56.76	$ 47.99
Antidilutive securities excluded from computation of earnings per share, exercise price, upper range limit	$ 76.49	$ 73.40

Share-Based Compensation (Sched

Share-Based Compensation (Schedule Of Stock Options Activity) (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)$ / sharesshares
Share-based Payment Arrangement [Abstract]
Outstanding at beginning of year, number of shares | shares	15,416
Outstanding at beginning of year, weighted-average exercise price | $ / shares	$ 56.36
Granted, number of shares | shares	2
Granted, weighted-average exercise price | $ / shares	$ 73.01
Exercised, number of shares | shares	(2,449)
Exercised, weighted-average exercise price | $ / shares	$ 48.43
Forfeited and expired, number of shares | shares	(152)
Forfeited and expired, weighted-average exercise price | $ / shares	$ 61.55
Outstanding end of year, number of shares | shares	12,817
Outstanding at end of year, weighted-average exercise price | $ / shares	$ 57.82
Outstanding at end of year, aggregate intrinsic value | $	$ 83,254
Outstanding at end of year, weighted-average remaining contractual term	6 years 29 days
Exercisable at end of year, number of shares | shares	6,269
Exercisable at end of year, weighted-average exercise price | $ / shares	$ 54.59
Exercisable at end of year, aggregate intrinsic value | $	$ 61,354
Exercisable at end of year, weighted-average remaining contractual term	4 years 6 months 18 days

Share-Based Compensation (Sch_2

Share-Based Compensation (Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions) (Details)	3 Months Ended
	Mar. 31, 2020$ / shares
Share-based Payment Arrangement [Abstract]
Expected volatility (%)	24.50%
Expected dividend rate	1.00%
Expected term (yrs)	6 years
Risk-free rate (%)	1.50%
Fair value per option	$ 17.53

Share-Based Compensation (Sch_3

Share-Based Compensation (Schedule Of Non-Vested Shares Activity) (Details) - Restricted Stock [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at beginning of year, number of shares | shares	2,634
Outstanding at beginning of year, weighted-average grant date fair value | $ / shares	$ 65.30
Granted, number of shares | shares	43
Granted, weighted-average grant date fair value | $ / shares	$ 72.28
Vested, number of shares | shares	(157)
Vested, weighted-average grant date fair value | $ / shares	$ 64.01
Forfeited, number of shares | shares	(22)
Forfeited, weighted-average grant date fair value | $ / shares	$ 65.49
Outstanding at end of year, number of shares | shares	2,498
Outstanding at end of year, weighted-average grant date fair value | $ / shares	$ 65.50

Share-Based Compensation (Compe

Share-Based Compensation (Compensation Expense Recognized In The Condensed Consolidated Statements Of Operations) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amounts charged against earnings, before income tax benefit	$ 35,387	$ 21,589
Amount of related income tax benefit recognized in earnings	6,443	4,201
Stock option and non-vested share compensation expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amounts charged against earnings, before income tax benefit	35,031	19,860
Associate stock purchase plan expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amounts charged against earnings, before income tax benefit	1,101	1,542
Amounts capitalized in software development costs, net of amortization
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amounts charged against earnings, before income tax benefit	$ (745)	$ 187

Schedule of Accumulated Other C

Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 30, 2019	Dec. 28, 2019	Dec. 29, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, net	$ (159,363)	$ (100,594)	$ (118,660)	$ (103,552)
OCI, before Reclassifications, Net of Tax, Attributable to Parent	(41,825)	2,958
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	1,122	0
Accumulated Foreign Currency Adjustment Attributable to Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, net	(126,893)	(100,618)	(106,347)	(102,939)
OCI, before Reclassifications, Net of Tax, Attributable to Parent	(20,546)	2,321
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	0	0
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, net	(31,886)	0	(12,578)	0
OCI, before Reclassifications, Net of Tax, Attributable to Parent	(20,430)	0
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	1,122	0
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, net	(584)	24	$ 265	$ (613)
OCI, before Reclassifications, Net of Tax, Attributable to Parent	(849)	637
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	$ 0	$ 0

Reclassification out of Accumul

Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 30, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other income, net	$ 5,595	$ 8,432
Income Tax Expense (Benefit)	36,812	40,157
Net earnings	147,159	166,219
Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net earnings	(1,122)	0
Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other income, net	(1,372)	0
Income Tax Expense (Benefit)	$ 250	$ 0

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options	$ 108
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	79
Stock Repurchase Program, Authorized Amount	3,700
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$ 1,030
Dividends Payable, Date Declared	Mar. 19, 2020
Dividends Payable, Amount Per Share | $ / shares	$ 0.18
Dividends Payable, Date to be Paid	Apr. 17, 2020
Dividends Payable, Date of Record	Apr. 3, 2020
Dividends Payable	$ 55
Treasury Stock, Value, Acquired, Cost Method	$ 650
Treasury Stock, Shares, Acquired | shares	9,200
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of recognition for remaining share-based compensation expense	2 years 6 months 7 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of recognition for remaining share-based compensation expense	1 year 10 months 17 days

Contingencies Contingencies (De

Contingencies Contingencies (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 29, 2018
Fujitsu [Member]
Commitments and Contingencies Disclosure [Abstract]
Loss Contingency, Management's Assessment and Process	As previously disclosed, we continue to be in dispute with Fujitsu Services Limited ("Fujitsu") regarding Fujitsu's obligation to pay amounts to us due upon the termination of a subcontract, including client receivables, in connection with Fujitsu's contract as the prime contractor in the National Health Service ("NHS") initiative to automate clinical processes and digitize medical records in the Southern region of England. The NHS terminated its contract with Fujitsu, which gave rise to the termination of our subcontract with Fujitsu. We filed a request for arbitration with the London Court of International Arbitration on April 22, 2019 seeking damages. On December 30, 2019, Fujitsu filed its Defense and Counterclaim (the "Counterclaim") in response. In its Counterclaim, Fujitsu defends against our claim in full and argues that we are liable to Fujitsu for: (i) £306 million in damages based on our alleged fraudulent misrepresentations inducing Fujitsu to enter into the subcontract; or (ii) alternatively, £173.8 million in damages based on our alleged breaches of the subcontract.
Loss Contingencies [Line Items]
Loss Contingency, Management's Assessment and Process	As previously disclosed, we continue to be in dispute with Fujitsu Services Limited ("Fujitsu") regarding Fujitsu's obligation to pay amounts to us due upon the termination of a subcontract, including client receivables, in connection with Fujitsu's contract as the prime contractor in the National Health Service ("NHS") initiative to automate clinical processes and digitize medical records in the Southern region of England. The NHS terminated its contract with Fujitsu, which gave rise to the termination of our subcontract with Fujitsu. We filed a request for arbitration with the London Court of International Arbitration on April 22, 2019 seeking damages. On December 30, 2019, Fujitsu filed its Defense and Counterclaim (the "Counterclaim") in response. In its Counterclaim, Fujitsu defends against our claim in full and argues that we are liable to Fujitsu for: (i) £306 million in damages based on our alleged fraudulent misrepresentations inducing Fujitsu to enter into the subcontract; or (ii) alternatively, £173.8 million in damages based on our alleged breaches of the subcontract.
Loss Contingency Accrual, Provision		$ 45
NextGen [Member]
Commitments and Contingencies Disclosure [Abstract]
Loss Contingency, Management's Assessment and Process	Cerner Health Services, Inc. ("Cerner HS"), a wholly owned subsidiary of Cerner Corporation, filed a lawsuit in the Chester County, Pennsylvania, Court of Common Pleas against NextGen Healthcare Information Systems, LLC ("NextGen") relating to a dispute arising out of a supplier relationship initially established between Siemens Health Services, Inc. and NextGen prior to the acquisition of the assets of Siemens Health Services, Inc. by Cerner HS in 2015. In September 2017, the court issued a preliminary injunction to prevent NextGen from refusing to honor certain contractual obligations to support Cerner HS's clients who use NextGen ambulatory EHR solutions. In September 2018, NextGen filed a counterclaim alleging breach of contract and tortious interference but did not specify its damages. In August 2019, NextGen provided an expert report alleging profit disgorgement damages of $135 million or, alternatively, $30.5 million in lost profit damages, but the report did not discuss how our actions allegedly caused NextGen's damages. In December 2019, we deposed NextGen's expert, gaining additional clarity on categories of alleged damages but not on the alleged theories of liability. A jury trial is set to begin on January 25, 2021. We believe NextGen's claims are without merit and will vigorously defend against them; however, there can be no assurances as to the outcome of the dispute. We have not concluded that a loss related to the claims raised by NextGen in its counterclaim is probable, nor have we accrued a liability related to these claims. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss in light of the inherent difficulty of predicting the outcome of litigation generally, the wide range of damages presented by NextGen's expert, and the continued lack of clarity on the causal connection between Cerner Corporation's and Cerner HS's actions and any alleged damages.
Loss Contingencies [Line Items]
Loss Contingency, Management's Assessment and Process	Cerner Health Services, Inc. ("Cerner HS"), a wholly owned subsidiary of Cerner Corporation, filed a lawsuit in the Chester County, Pennsylvania, Court of Common Pleas against NextGen Healthcare Information Systems, LLC ("NextGen") relating to a dispute arising out of a supplier relationship initially established between Siemens Health Services, Inc. and NextGen prior to the acquisition of the assets of Siemens Health Services, Inc. by Cerner HS in 2015. In September 2017, the court issued a preliminary injunction to prevent NextGen from refusing to honor certain contractual obligations to support Cerner HS's clients who use NextGen ambulatory EHR solutions. In September 2018, NextGen filed a counterclaim alleging breach of contract and tortious interference but did not specify its damages. In August 2019, NextGen provided an expert report alleging profit disgorgement damages of $135 million or, alternatively, $30.5 million in lost profit damages, but the report did not discuss how our actions allegedly caused NextGen's damages. In December 2019, we deposed NextGen's expert, gaining additional clarity on categories of alleged damages but not on the alleged theories of liability. A jury trial is set to begin on January 25, 2021. We believe NextGen's claims are without merit and will vigorously defend against them; however, there can be no assurances as to the outcome of the dispute. We have not concluded that a loss related to the claims raised by NextGen in its counterclaim is probable, nor have we accrued a liability related to these claims. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss in light of the inherent difficulty of predicting the outcome of litigation generally, the wide range of damages presented by NextGen's expert, and the continued lack of clarity on the causal connection between Cerner Corporation's and Cerner HS's actions and any alleged damages.
Lowe [Member]
Commitments and Contingencies Disclosure [Abstract]
Loss Contingency, Management's Assessment and Process	On April 4, 2018, Ruby L. Lowe, Guardian ad Litem for Michael A. Taylor, filed a lawsuit against Cerner Corporation in the Circuit Court for Clarke County, Virginia. On November 4, 2019, the Court substituted Cerner HS in place of Cerner Corporation as the defendant in the lawsuit. Plaintiff asserts claims of negligent product liability, negligence, and violations of the Virginia Consumer Protection Act. Plaintiff alleges that Mr. Taylor suffered injuries following his medical treatment at Virginia Hospital Center, a client of Cerner HS. Specifically, plaintiff asserts a software defect contributed to an order to monitor pulse oxygen not starting until a day after it was ordered, allegedly contributing to Taylor's injury. Plaintiff seeks an award of $50 million. A jury trial is set to begin on September 8, 2020. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss in light of the inherent difficulty of predicting the outcome of litigation generally, the wide range of damages presented by plaintiff, and the difficulty plaintiff will have proving that the solution was the proximate cause of plaintiff's harm.
Loss Contingencies [Line Items]
Loss Contingency, Management's Assessment and Process	On April 4, 2018, Ruby L. Lowe, Guardian ad Litem for Michael A. Taylor, filed a lawsuit against Cerner Corporation in the Circuit Court for Clarke County, Virginia. On November 4, 2019, the Court substituted Cerner HS in place of Cerner Corporation as the defendant in the lawsuit. Plaintiff asserts claims of negligent product liability, negligence, and violations of the Virginia Consumer Protection Act. Plaintiff alleges that Mr. Taylor suffered injuries following his medical treatment at Virginia Hospital Center, a client of Cerner HS. Specifically, plaintiff asserts a software defect contributed to an order to monitor pulse oxygen not starting until a day after it was ordered, allegedly contributing to Taylor's injury. Plaintiff seeks an award of $50 million. A jury trial is set to begin on September 8, 2020. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss in light of the inherent difficulty of predicting the outcome of litigation generally, the wide range of damages presented by plaintiff, and the difficulty plaintiff will have proving that the solution was the proximate cause of plaintiff's harm.

Segment Reporting (Summary Of T

Segment Reporting (Summary Of The Operating Information) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 30, 2019
Segment Reporting Information [Line Items]
Revenues	$ 1,411,741	$ 1,389,877
Cost of revenues	254,416	253,204
Operating expenses	978,949	938,729
Total costs and expenses	1,233,365	1,191,933
Operating earnings (loss)	178,376	197,944
Domestic Segment
Segment Reporting Information [Line Items]
Revenues	1,246,415	1,230,830
Cost of revenues	228,567	228,559
Operating expenses	570,094	572,018
Total costs and expenses	798,661	800,577
Operating earnings (loss)	447,754	430,253
International Segment [Member]
Segment Reporting Information [Line Items]
Revenues	165,326	159,047
Cost of revenues	25,849	24,645
Operating expenses	66,555	68,169
Total costs and expenses	92,404	92,814
Operating earnings (loss)	72,922	66,233
Other
Segment Reporting Information [Line Items]
Operating expenses	342,300	298,542
Total costs and expenses	342,300	298,542
Operating earnings (loss)	$ (342,300)	$ (298,542)